Frontier Bio

Our Mission: End the Organ Shortage & Replace Animal Testing Through Engineered Human Tissue

Print
Claim My Business
Categories
Technology, Financial Services, Healthcare & Medical
Min Investment
$100
No. Investors
73
Website
frontierbio.com

Key Deal Facts

$5.5M in Cumulative Sales: Validated demand from customers for tissue models built with human cells.
Transforming Medicine: Reducing animal studies and advancing implantable human tissue.
Market Opportunity: Multi-billion-dollar market for human tissue models and vascular grafts
$4.1M Raised to Date: Strong investor confidence with $1.6M committed in the current round.
Patent Families: Defensible IP covering core tissue biofabrication and vascular graft technologies.
Elite Backing & Support: Funded by NSF SBIR and a Nobel Laureate, and advised by George Church.
Trusted by Industry Leaders: Clients include Mayo Clinic and Intuitive Surgical.

Management Team / Advisory Board Bios

VC-Backed
Raised $250K or more from a venture firm, Eric Bennett, MScCEOEric is a serial entrepreneur & biomedical engineer. As past CTO at Aether, he designed advanced, low-cost 3D bioprinters. His deep-tech expertise spans DNA assembly, microfluidics, biofabrication, optogenetics, & brain-computer interfaces.frontierbio.com, Dr. Sam Pashneh-Tala, PhDCTOA recognized expert in tissue-engineered blood vessels, Sam authored the subject’s seminal, ~1,000-citation review paper. He completed his PhD and fellowship in the field and previously ran an advanced medical device and tissue engineering consultancy., Dr. George M. Church, PhDAdvisorHarvard Medical School genetics professor and synthetic biology pioneer. Member of the National Academy of Sciences and National Academy of Engineering. Co-founder of multiple biotech companies, including Editas Medicine and Colossal Biosciences., Ravi Belani, MBA, MSAdvisorFounder & Managing Director of Alchemist Accelerator, backing unicorns like LaunchDarkly and Rigetti. Stanford lecturer on entrepreneurship. Previously led early investments in Twitch and PubMatic at DFJ. MBA, Harvard Business School., Dr. Jamie Cate, PhDAdvisorProfessor at UC Berkeley and Faculty Scientist at Lawrence Berkeley National Laboratory. Elected member of the American Academy of Arts and Sciences. Specializes in translating molecular mechanisms into therapeutics and sustainable biofuels applications., Dr. Rami El Assal, DDSAdvisorManaging Partner at Boutique Venture Partners, clinician-scientist with postdoctoral training at both Harvard Medical School and Stanford, and author of "Towards Artificial Tissue Models: Past, Present, and Future of 3D Bioprinting.", Dr. Jaimie Shores, MDAdvisorHand and peripheral nerve surgeon specializing in reconstructive microsurgery. Former Clinical Director of the Hand and Arm Transplant Program at Johns Hopkins; led the vascular team for the institution’s first bilateral arm transplant.
Amount Raised : $1,679,915
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Research Reports

No reports have been submitted

Become a Reporter

0 Comments